The most commonly reported adverse events (observed in less than 5% of clinical trial participants) were nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease The label for Zepbound includes a boxed warning regarding thyroid C-cell tumors
Incidence rates for the 4 outcomes were elevated among GLP-1 agonists compared with bupropion-naltrexone users (Table 1)
The compound is prepared and packaged to support consistent handling within professional research environments
How to Afford Zepbound (Tirzepatide) Safely For many patients struggling with obesity, Zepbound (tirzepatide) has emerged as a promising treatment option
This kind of personalized adjustment, guided by our experienced team, is key to successful treatment
Doctors may not need to require patients discontinue GLP-1 agonists such as Wegovy and Ozempic for seven days before any surgery or endoscopy, according to a Houston Methodist Hospital-led study